vindesine / Generic mfg. - LARVOL DELTA

Efficacy and safety of zanubrutinib combined with g-CVP (Obinutuzumab, Cyclophosphamide, Vindesine, Prednisone) for first-line treatment of follicular lymphoma (ASH 2025) - P2 | "Conclusion This retrospective study demonstrates that the combination of zanubrutinib with G-CVP was highly effective and well-tolerated in previously untreated FL. Based on these findings, we plan to conduct a phase II, single-arm, multicenter clinical trial (NCT06918015) to further evaluate the efficacy and safety of ZG-CVP as first-line therapy for FL."

Clinical • Cardiovascular • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Neutropenia • Pneumonia • Respiratory Diseases • Thrombocytopenia • Thrombosis

Single-center experience with mitoxantrone hydrochloride liposome-based therapy for patients with myeloid sarcoma (ASH 2025) - "Anotherpatient experienced a recurrence after consolidation treatment and died due to complicationsfollowing CAR-T and allo-HSCT therapy.Two patients with relapsed MS (with or without BM involvement) were treated with Lipo-MIT,cytarabine, and etoposide (MAE) ± PD-1...After one cycle of treatment with the VMCP (vindesine, Lipo-MIT, cyclophosphamide and dexamethasone) regimen, both BM and extramedullary sites wereassessed as CR, with negative minimal residual disease (MRD) detected by flow cytometry... Our results indicated the initial efficacy of Lipo-MIT for de novo MS, demonstrated by its ability to reduceor eliminate tumor burden within two cycles. Sequential allo-HSCT following remission could extendsurvival duration. Further large-sample analyses are anticipated to comprehensively elucidate theefficacy and safety of the Lipo-MIT-based regimen."

Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Chronic Myeloid Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Pneumonia • Respiratory Diseases • Sarcoma • PD-1

Safety and efficacy of low-intensity chemotherapy combined with sequential blinatumomab and inotuzumab ozogamicin immunotherapy in newly diagnosed B-ALL patients unfit/fit-declined for intensive chemotherapy: A prospective, open-label, single-arm Phase II trial in progress (ASH 2025) - P1/2, P2 | "The study will enroll 26 newly diagnosed B-ALL pts aged ≥60 yearsor 15-60 years, who are either unfit for intensive chemotherapy or fit but have declined it (fit-declined).Unfit pts must have Eastern Cooperative Oncology Group performance status ≥2 or at least one of: 1)congestive heart failure requiring therapy or left ventricular ejection fraction of ≤50%, 2) diffusingcapacity of carbon monoxide of ≤65% or forced expiratory volume in the first second of ≤65%, 3)creatinine >2×the upper limit of normal [ULN] or creatinine clearance 1.5×ULN or aspartate aminotransferase/alanine aminotransferase/alkaline phosphatase >3×ULN), 5)active uncontrolled infection, 6), cognitive impairment, 7) other chemotherapy-contraindicatedcomorbidities.Induction therapy consists of low-intensity chemotherapy combined with BiTE with or without TKIs.Regimen included dexamethasone 8 mg/m²/day intravenously injection (IV), days 1-14, vindesine 4 mg, IV,day 7,..."

Clinical • P2 data • Acute Lymphocytic Leukemia • Alzheimer's Disease • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Cognitive Disorders • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Infectious Disease • Leukemia • CD22

Efficacy and safety of R-CDOP in treatment-Naïve non-Hodgkin lymphoma with high tumor burden: A multicenter, prospective study (ASH 2025) - P=N/A | "Pegylated liposomaldoxorubicin (PLD) offers a promising alternative to conventional doxorubicin, leveraging enhancedpermeability and retention effects for longer circulation and less cardiotoxicity...Thepatients received R-CDOP: Rituximab (375mg/m2, d0), PLD (30-35mg/ m2, d1), Cyclophosphamide(750mg/ m2, d1), Vindesine (3mg/ m2, d1) / Vincristine (1.4mg/m2, d1) and Prednisone (60mg/ m2, d1-5)every 21 days for 4 (Limited-stage lymphoma) or 6 (Advanced lymphoma) cycles with an additional 2cycles of Rituximab therapy... The preliminary results of the study demonstrated promising efficacy and a manageablesafety profile for the R-CDOP regimen in treatment-naïve NHL patients with high tumor burden,supporting further investigation."

Clinical • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Heart Failure • Hematological Disorders • Hematological Malignancies • Hepatology • Large B Cell Lymphoma • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • CD20

Efficacy and Safety of Avatrombopag on Thrombocytopenia after Chemotherapy in Acute Leukaemia (ASH 2023) - "Chemotherapy regiments for patients with AML included decitabine combined with venetoclax (n=5), decitabine combined with arabinoside (n=3), arsenic trioxide combined with retinoic acid (n=3), azacytidine combined with venetoclax (n=2), azacytidine combined with medium-dose arabinoside (n=1). Chemotherapy regiments for patients with ALL included CD19 specific CAR-T cells (n=3), decitabine (n=2), blinatumomab (n=2), IVP (idarubicin, vindesine, and prednisone) (n=1), azacytidine combined with venetoclax and chidamide (n=1)... Avatrombopag is effective on increasing platelet counts in patients with acute leukaemia after chemotherapy, with a good safety profile. It is a suitable therapeutic option for thrombocytopenia after chemotherapy."

Clinical • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Hepatology • Immune Thrombocytopenic Purpura • Leukemia • Oncology • Thrombocytopenia • Thrombocytopenic Purpura

The Efficacy and Safety of the Third Generation TKI Olverembatinib in Adult Ph+ Acute Lymphoblastic Leukemia with Relapsed Disease or Persistent MRD Bridging to Allo-HSCT: A Case Series from a Single Center (ASH 2023) - "The Olverembatinib involving regimen included: Olverembatinib and Venetoclax in combination with VP based low intensive chemotherapy (Vindesine /Prednisone), Olverembatinib+Blinatumomab, Olverembatinib + INO. ConclusionThis work suggests that Olverembatinib showed a profound response rate and was well tolerated in MRD clearance prior to allo-HSCT in Ph+ALL with disease recurrence and persistently MRD positive. Larger prospective studies are needed."

Clinical • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Cardiovascular • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Leukemia • Oncology • ABL1 • BCR

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Preliminary Results from a Phase II Study (ASH 2023) - P=N/A | "The Smart Start study demonstrated that induction therapy with rituximab (R), lenalidomide, and ibrutinib resulted in a high overall response rate (ORR) in patients with newly diagnosed DLBCL (Westin J, et al...Subsequently, patients who achieved at least mini response (miniR, a reduction in tumor lesions by 25%-50%) were administered additional 6 cycles of PRO-miniCHOP regimen (PRO with reduced-dose CHOP regimen [cyclophosphamide, 400 mg/m 2, d2; doxorubicin/liposomal doxorubicin, 25 mg/m 2/15 mg/m 2, d2; vindesine, 2 mg, d2; and dexamethasone, 7... The present study provided preliminary evidence supporting the use of the PRO-miniCHOP regimen in elderly patients with newly diagnosed DLBCL. More clinical data will be updated from this ongoing study."

Clinical • IO biomarker • P2 data • Atrial Fibrillation • B Cell Lymphoma • Cardiovascular • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • Hypertension • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • BCL2 • MYC

Pomalidomide, Rituximab, Orelabrutinib, and Minichop-like (PRO-miniCHOP) in Elderly Patients with Newly Diagnosed Diffuse Large-B Cell Lymphoma: Updated Results from a Phase II Study (ASH 2024) - P=N/A | "The Smart Start study illustrated that the utilization of rituximab (R), lenalidomide, and ibrutinib as induction therapy yielded a notably high overall response rate (ORR) among pts with newly diagnosed DLBCL (Westin J, et al...Subsequently, pts who achieved at least mini response (miniR, a reduction in tumor lesions by 25%-50%) were administered additional 6 cycles of PRO-miniCHOP regimen (PRO with a reduced-dose CHOP regimen [cyclophosphamide, 400 mg/m2, d2; doxorubicin/liposomal doxorubicin, 25 mg/m2/15 mg/m2, d2; vindesine, 2 mg, d2; and dexamethasone, 7.5 mg/m2, d2-6])...Those who responded to the induction therapy may experience a synergistic antitumor effect and achieve a high CRR with subsequent PRO-miniCHOP therapy and during follow-up assessments. While AEs were prevalent, the majority were controllable and did not hinder the continuation or efficacy of treatment."

Clinical • IO biomarker • P2 data • Anemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • BCL2 • MYC

Reduced-Dose Chemotherapy Followed By Blinatumomab As Induction Therapy in Treatment of Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia - Interim Results from a Multicenter, Single-Arm, Phase 2 Study (ASH 2023) - P2 | "The induction regimen comprised reduced intensity chemotherapy (idarubicin 8 mg/m2 on day 1, vindesine 4 mg on day 1, and dexamethasone 9 mg/m2/day from day 1-7) followed by 2 weeks of blinatumomab (9 ug/day from day 8-14, 28 ug/day from day 15-21)...Consolidation therapy was given after achieving ORR with recommended multidrug combination chemotherapy (including high-dose methotrexate or cytarabine combined with asparaginase) or alternating with blinatumomab (28 ug/day for 28 days)... These preliminary results indicate that the reduced intensity chemotherapy followed by blinatumomab is an effective regimen in adults with newly diagnosed Ph-negative BCP-ALL, resulting in favorable response rates, deep remission, and low-grade treatment-related AEs. These promising findings may provide a rationale for integrating blinatumomab into future induction therapy recommendations."

Clinical • P2 data • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Neutropenia • Pediatrics • Pneumonia • Respiratory Diseases • Septic Shock • Transplantation • CRLF2 • IKZF1 • KMT2A • P2RY8

Treatment and Outcome of ATL Diagnosed in 2021 to 2023 By the Kagoshima ATL Registry (ASH 2024) - "Among them, CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone), VCAP-AMP-VECP (VCAP : vincristine, cyclophosphamide, doxorubicin, and prednisolone, AMP : doxorubicin, ranimustine, and prednisolone, and VECP : vindesine, etoposide, carboplatin, and prednisolone), any chemotherapy by cytotoxic agents combined with mogamulizumab (Moga+CTx), and CHP therapy combined with brentuximab vedotin (BV-CHP) were performed in 30.0 %, 28.3 %, 28.3 %, and 13.4% of patients, respectively. BV or Moga with or without CTx were most frequently used in the second-line treatment (n=81). This registration is expected to provide real-world data of ATL by regional registry in one of the world's most endemic area in HTLV-1 under the circumstances of the decreasing of HTLV-1 infected individuals in younger people and recent Introduction of novel therapeutic agents including tucidinostat and valemetostat in Japan."

Adult T-Cell Leukemia-Lymphoma • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Pediatric Patients with Acute Lymphoblastic Leukemia Treated with Blinatumomab in a Real-World Study (ASH 2023) - "The patients received a 7-day pre-treatment VCP regimen consisting of intravenous infusions of cyclophosphamide 800 mg/m 2 on day 1, vindesine 3 mg/m 2 on day 1, prednisone 1-2 mg/kg on days 1 to 7 (VCP regimen), followed by 28 days of treatment with blinatumomab at 5µg/m 2/day on the first 1 to 7 days and 15 µg/m 2/day on the next 8 to 28 days...Blinatumomab was administered to 5 patients in the induction remission period, and for 2 patients, blinatumomab was administered in consolidation after inotuzumab ozogamicin (INO)...Blinatumomab consolidation therapy was also effective in patients pretreated with INO. Blinatumomab consolidation after induction therapy could be a new and effective strategy for the treatment of patients with newly diagnosed B-ALL."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Pediatrics • Transplantation • CRLF2 • CSF1R • PBX1 • SSBP2

Application of Inotuzumab Ozogamicin in Children with B-ALL (ASH 2024) - "The patients were pretreated for 5 days with VAD regimen : Vindesine 3mg/m2,d1; Cytarabine 100mg/m2,d1-5; Dexamethasone 6mg/m2,d1-5 (dexamethasone can be replaced with methylprednisolone if the patient was intolerant)...Five patients were treated with InO during the induction therapy, and six were treated with InO following by the Blinatumomab consolidation therapy...However, immunoglobulin decline was associated with the risk of infection and required gamma globulin support therapy. We suggest that InO shall be increasingly applied in children with B-ALL who were initially diagnosed as high risk and MRD-positive after induction therapy."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pediatrics • CD22 • CRLF2 • CSF1R • FLT3 • IKZF1 • PBX1 • SSBP2 • TP53

The Treatment of Burkitt Lymphoma with the Berlin-Frankfurt-Münster Protocol with Rituximab and Autologous Transplantation (ASH 2023) - "Treatment plan consisted of 3 blocks, A (ifosfamide, vincristine, methotrexate, etoposide, cytarabine), B (vincristine, cyclophosphamide, methotrexate, doxorubicin) and C (vindesine, methotrexate, etoposide, cytarabine), each repeated twice, every 28 days...Autologous stem cells were reinfused (ASCT) at the end of the 6-blocks after BEAM (carmustine, etoposide, cytarabine, melphalan) conditioning, when feasible...Infections occurred in 60% of patients; grade 4 and fatal sepsis in 14% and 8% of cases. Intensive treatment according to BFM protocol, with rituximab and ASCT, appears feasible, safe and highly effective in adult patients with BL, as confirmed by long-term survival rates."

Clinical • Anemia • Burkitt Lymphoma • Cardiovascular • Hematological Disorders • Hematological Malignancies • Human Immunodeficiency Virus • Infectious Disease • Lymphoma • Mucositis • Neutropenia • Oncology • Septic Shock • Thrombocytopenia • Transplantation

A Prospective, Exploratory, Phase II Study of the Xpo-1 Inhibitor Selinexor in Combination with RCHOP in Double/Triple-Hit Large B-Cell Lymphoma (ASH 2023) - "The optimal treatment for DH/TH lymphoma remains unclear, although outcomes are inadequate with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP) alone...The initial dose of each drug in this regimen is as follows (repeat every 21 days, 6 cycles in total): rituximab: 375mg/m 2, d0; vindesine 4mg, d1; epirubicin 75mg/m 2, d1 (or liposomal doxubicin 35mg/m 2, d1); cyclophosphamide: 750mg/m 2, d1; prednisone: 100mg, d1-5; selinexor 60mg orally once a week...Dynamic testing of ctDNA demonstrated deep remission to chemotherapy. Based on the encouraging results of the current study, a large scale, multicenter trial is needed to further investigate this promising regimen."

Clinical • Combination therapy • IO biomarker • P2 data • Anemia • B Cell Lymphoma • CNS Disorders • Diffuse Large B Cell Lymphoma • Fatigue • Hematological Malignancies • Infectious Disease • Large B Cell Lymphoma • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Thrombocytopenia • BCL6 • BTG2 • ETS1 • IGLL5 • NFKBIE • OSBPL10 • SOCS1 • TMSB4X • TNFRSF14 • TP53 • XPO1

Olverembatinib (HQP1351) Combined with Chemotherapy Is an Effective and Safe Treatment in Patients with Philadelphia Chromosome-Positive (Ph +) Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia in Lymphoid Blast Phase (CML-LBP) That Failed TKI-Based Regimens (ASH 2023) - "The 15 R/R patients (11, Ph + ALL; 4, CML-BP) received olverembatinib 30 or 40 mg on alternate days combined with VP (vindesine 4 mg once per week for 4 weeks and prednisone 1 mg/kg for 3 weeks and tapered at the fourth)...Among the 16 patients with molecular resistance to TKI-based chemotherapy (imatinib [n = 4]; dasatinib [n = 9]; flumatinib [n = 3]), 2 received olverembatinib monotherapy, 7 olverembatinib plus VP, and 7 hyper-CVAD, of whom 8 received subsequent allogeneic transplantation...Treatment-related nonhematologic severe adverse events were observed in 3 patients, including (each) stable angina pectoris, severe pneumonia, and fatal Klebsiella sepsis. Conclusions Olverembatinib-based chemotherapy is effective and safe in patients with R/R and molecular resistant Ph + ALL or CML-LBP."

Clinical • Acute Lymphocytic Leukemia • Central Nervous System Leukemia • Chronic Myeloid Leukemia • Hematological Malignancies • Infectious Disease • Pneumonia • Respiratory Diseases • Septic Shock • ABL1

UHRF1-Mediated Epigenetic Reprogramming Regulates Glycolysis to Promote Progression of B-Cell Acute Lymphoblastic Leukemia (ASH 2023) - "In vitro experiments, knockout of gene UHRF1 promoted the cycle arrest and apoptosis of B-ALL tumor cell line (Reh and nalm6), inhibited the proliferation of cells, and improved the drug sensitivity of vindesine. Furthermore, UM164 demonstrated the ability to inhibit the proliferation of B-ALL cells both in vitro and in vivo, leading to prolonged survival in a B-ALL mouse model. In conclusion, we have unraveled the molecular mechanisms of epigenetic and metabolic rearrangements in relapsed/refractory B-ALL, and have provided potential targeted therapeutic strategies to improve its unfavorable prognosis."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • T Acute Lymphoblastic Leukemia • HSPB1 • IGFBP2 • UHRF1

Combination of Olverembatinib and VP Regimen As First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ASH 2023) - "The upfront use of third generation TKI ponatinib has improved the frequency of complete molecular response (CMR) and the overall survival rate to a greater extent...They received three cycles of OVP regimen(for 28 days each cycle :olverembatinib 40mg qod d1-28,Vindesine 4mg d1,8,15,22,Prednisone1mg/Kg/d d1-21,0.5mg/kg/dd22-28). Twelve intrathecal injections of cytarabine alternating with methotrexate were designed as central nervous system prophylaxis in the following therapy after the diagnosis...The trial is ongoing. we need more time to observe."

Clinical • Acute Lymphocytic Leukemia • Cardiovascular • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • ABL1

Adult Langerhans Cell Histiocytosis with Liver Involvement (ASH 2023) - "In total, 99 patients (86.1%) received first-line systematic treatment, including 76 patients who received chemotherapies (methotrexate/cytarabine regimens, cytarabine monotherapy, vindesine/prednisone-based regimens, cladribine monotherapy and corticosteroid), 15 patients who received immunomodulatory drugs (IMiDs) therapies (thalidomide/cyclophosphamide/dexamethasone regimens and lenalidomide/dexamethasone regimens) and 8 patients who received target therapies (BRAF inhibitors and MEK inhibitors). Elevated hsCRP and 3 or more abnormal live function tests predict poor outcomes. Target therapy or iMIDs-based therapy showed better outcomes."

Clinical • Fibrosis • Hepatology • Immunology • Langerhans Cell Histiocytosis • Liver Failure • CRP • MAP2K1

A Multicenter, Prospective Clinical Study of the R-CDOP Regimen in Previously Untreated Non-Hodgkin Lymphoma with High Tumor Burden (ASH 2023) - P=N/A | "Pegylated liposomal doxorubicin (PLD) is a promising alternative drug to the current regimen, with a safety and efficacy profile through the enhanced permeability and retention effect and longer circulation1-3, and especially less cardiotoxic compared with traditional anthracyclines4...The patients received PLD (30-35mg/ m2, d1) plus Rituximab (375mg/m2, d0), Cyclophosphamide (750mg/ m2, d1), Vindesine (3mg/ m2, d1) / Vincristine (1.4mg/m2, d1) and Prednisone (60mg/ m2, d1-5) Q3W for 4 (Limited-stage lymphoma) or 6 (Advanced lymphoma) cycles with an additional 2 cycles of Rituximab therapy... The preliminary results of the study indicate that the R-CDOP regimen is safe and shows promising efficacy for treating TN NHL with a high tumor burden."

Clinical • Anemia • B Cell Lymphoma • Cardiovascular • Congestive Heart Failure • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Heart Failure • Hematological Disorders • Hematological Malignancies • Hepatology • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • CD20

Clinical Characteristics, Genomic Profiling and Outcomes of Langerhans Cell Histiocytosis in Adults with Single System Multifocal Disease (ASH 2023) - "Systemic therapy included 18 received cytarabine monotherapy, six received methotrexate combined with cytarabine, four received vindesine and prednisone-based regimens, and two who had CNS-risk lesions involvement received BRAF inhibitors (Figure1 B). A. Next-generation sequencing of lesion tissues of LCH in adults with single-system multifocal disease (SS-m); B. Treatment and outcomes of adult patients with SS-m; C. Progression-free survival (PFS) according to first-line treatment; D. PFS according to CNS-risk lesions involvement at baseline"

Clinical • Langerhans Cell Histiocytosis • Musculoskeletal Pain • Pain • MAP2K1

Combination of Olverembatinib and VP Regimen for Newly Diagnosed Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ASH 2024) - "The combination of third-generation TKI Ponatinib can achieve a higher percentage of early molecular remission and significantly improve the prognosis, but the safety is unsatisfactory; Olverembatinib is a novel third-generation TKI, which has demonstrated better efficacy and safety in patients with CML; This study is intended to explore the efficacy and safety of Olverembatinib in combination with VP regimen in the treatment of newly diagnosed adult PH+ALL...Patients were treated with a combination of Olverembatinib (40mg QOD d1-28), Vindesine 4mg d1,8,15, Prednisone1mg/Kg/d d1-14, and then gradually tapered off for 28d in induction therapy, Post-induction treatment to be decided by each centre...Conclusion The combination of Olverembatinib and reduced-intensity chemotherapy (VP) is a safe and effective regimen in patients with newly diagnosed Ph+ ALL. The regimen results in high rates of CMR in the absence of intensive chemotherapy, and promises to improve long-term..."

Clinical • Acute Lymphocytic Leukemia • Infectious Disease • IKZF1

Blastic plasmacytoid dendritic cell tumor: A case report (EADV 2025) - "Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive malignancy with a distinct clinical and immunophenotypic profile, notably marked by its early cutaneous involvement and expression of plasmacytoid dendritic cell markers such as CD4, CD56, and TCL1. Given its poor prognosis with conventional chemotherapy alone, early diagnosis and timely therapeutic intervention are crucial. Allogeneic stem cell transplantation, particularly when performed early, significantly improves survival outcomes."

Case report • Clinical • Acute Myelogenous Leukemia • Crohn's disease • Gastroenterology • Hematological Malignancies • Immunology • Inflammatory Bowel Disease • Leukemia • Oncology • Vasculitis • CD20 • CD4 • CD8 • NCAM1 • TNFRSF8

Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients (clinicaltrials.gov) - P2 | N=27 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University

New P2 trial • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy (clinicaltrials.gov) - P2 | N=26 | Recruiting | Sponsor: The First Affiliated Hospital of Soochow University | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Adult pancreatoblastoma: Systematic review of the literature and case report of a young adult patient. (PubMed, World J Gastrointest Oncol) - "Common pancreatoblastoma features include acinar groups, chromogranin, chymotrypsin, squamous corpuscles, synaptophysin and trypsin on histology and adenomatous polyposis coli, B-cell lymphoma/leukemia 10, catenin beta 1, and Wnt/beta-catenin genetic mutations."

Journal • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pancreatic Cancer • Solid Tumor • CTNNB1 • SYP